Lund, Sweden – 29 April 2016 – BioInvent International AB (publ) (BINV) today announced that the company’s total number of shares as per 29 April 2016 amounts to 282,721,619 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 97,751,376 shares and from the directed issue of 22,051,282 shares to Omega Fund IV, announced on 16 February 2016.
 
 
To the editors:

About BioInvent
BioInvent International AB develops immune oncology drugs. With one of the world’s largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)70716 89 30
[email protected]

BioInvent International AB (publ)
Co. reg. No: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46 286 85 50
[email protected]
www.bioinvent.com
 
 
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 29 April 2016.